Literature DB >> 23742080

TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia.

Alexandra M Nicholson1, Nicole A Finch, Aleksandra Wojtas, Matt C Baker, Ralph B Perkerson, Monica Castanedes-Casey, Linda Rousseau, Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Ging-Yuek R Hsiung, Ian R Mackenzie, Elizabeth Finger, Bradley F Boeve, Nilüfer Ertekin-Taner, Neill R Graff-Radford, Dennis W Dickson, Rosa Rademakers.   

Abstract

Frontotemporal lobar degeneration (FTLD) is the second leading cause of dementia in individuals under age 65. In many patients, the predominant pathology includes neuronal cytoplasmic or intranuclear inclusions of ubiquitinated TAR DNA binding protein 43 (FTLD-TDP). Recently, a genome-wide association study identified the first FTLD-TDP genetic risk factor, in which variants in and around the TMEM106B gene (top SNP rs1990622) were significantly associated with FTLD-TDP risk. Intriguingly, the most significant association was in FTLD-TDP patients carrying progranulin (GRN) mutations. Here, we investigated to what extent the coding variant, rs3173615 (p.T185S) in linkage disequilibrium with rs1990622, affects progranulin protein (PGRN) biology and transmembrane protein 106 B (TMEM106B) regulation. First, we confirmed the association of TMEM106B variants with FTLD-TDP in a new cohort of GRN mutation carriers. We next generated and characterized a TMEM106B-specific antibody for investigation of this protein. Enzyme-linked immunoassay analysis of progranulin protein levels showed similar effects upon T185 and S185 TMEM106B over-expression. However, over-expression of T185 consistently led to higher TMEM106B protein levels than S185. Cycloheximide treatment experiments revealed that S185 degrades faster than T185 TMEM106B, potentially due to differences in N-glycosylation at residue N183. Together, our results provide a potential mechanism by which TMEM106B variants lead to differences in FTLD-TDP risk. We studied the p.T185S TMEM106B genetic variant previously implicated in frontotemporal dementia with TAR DNA binding protein 43 pathology caused by progranulin mutations. Our cell culture studies provide evidence that the protective S185 isoform is degraded more rapidly than T185 TMEM106B, potentially due to differences in glycosylation. These findings suggest that low TMEM106B levels might protect against FTLD-TDP in these patients.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  TMEM106B; frontotemporal dementia; glycosylation; progranulin

Mesh:

Substances:

Year:  2013        PMID: 23742080      PMCID: PMC3766501          DOI: 10.1111/jnc.12329

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

2.  Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.

Authors:  Carlos Cruchaga; Caroline Graff; Huei-Hsin Chiang; Jun Wang; Anthony L Hinrichs; Noah Spiegel; Sarah Bertelsen; Kevin Mayo; Joanne B Norton; John C Morris; Alison Goate
Journal:  Arch Neurol       Date:  2011-01-10

3.  TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease.

Authors:  Nicola J Rutherford; Minerva M Carrasquillo; Ma Li; Gina Bisceglio; Joshua Menke; Keith A Josephs; Joseph E Parisi; Ronald C Petersen; Neill R Graff-Radford; Steven G Younkin; Dennis W Dickson; Rosa Rademakers
Journal:  Neurology       Date:  2012-08-01       Impact factor: 9.910

4.  Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion.

Authors:  Kevin F Bieniek; Melissa E Murray; Nicola J Rutherford; Monica Castanedes-Casey; Mariely DeJesus-Hernandez; Amanda M Liesinger; Matthew C Baker; Kevin B Boylan; Rosa Rademakers; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2012-09-28       Impact factor: 17.088

5.  Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study.

Authors:  Roberta Ghidoni; Elena Stoppani; Giacomina Rossi; Elena Piccoli; Valentina Albertini; Anna Paterlini; Michela Glionna; Eleonora Pegoiani; Luigi F Agnati; Chiara Fenoglio; Elio Scarpini; Daniela Galimberti; Michela Morbin; Fabrizio Tagliavini; Giuliano Binetti; Luisa Benussi
Journal:  Neurodegener Dis       Date:  2011-11-26       Impact factor: 2.977

6.  TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.

Authors:  Alice S Chen-Plotkin; Travis L Unger; Michael D Gallagher; Emily Bill; Linda K Kwong; Laura Volpicelli-Daley; Johanna I Busch; Sebastian Akle; Murray Grossman; Vivianna Van Deerlin; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-08-15       Impact factor: 6.167

7.  Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration.

Authors:  Christina M Lang; Katrin Fellerer; Benjamin M Schwenk; Peer-Hendrik Kuhn; Elisabeth Kremmer; Dieter Edbauer; Anja Capell; Christian Haass
Journal:  J Biol Chem       Date:  2012-04-17       Impact factor: 5.157

8.  The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function.

Authors:  Owen A Brady; Yanqiu Zheng; Kira Murphy; Marshall Huang; Fenghua Hu
Journal:  Hum Mol Genet       Date:  2012-11-06       Impact factor: 6.150

9.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

10.  TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort.

Authors:  Julie van der Zee; Tim Van Langenhove; Gernot Kleinberger; Kristel Sleegers; Sebastiaan Engelborghs; Rik Vandenberghe; Patrick Santens; Marleen Van den Broeck; Geert Joris; Jolien Brys; Maria Mattheijssens; Karin Peeters; Patrick Cras; Peter P De Deyn; Marc Cruts; Christine Van Broeckhoven
Journal:  Brain       Date:  2011-03       Impact factor: 13.501

View more
  46 in total

1.  Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology.

Authors:  Hyun-Sik Yang; Charles C White; Hans-Ulrich Klein; Lei Yu; Christopher Gaiteri; Yiyi Ma; Daniel Felsky; Sara Mostafavi; Vladislav A Petyuk; Reisa A Sperling; Nilüfer Ertekin-Taner; Julie A Schneider; David A Bennett; Philip L De Jager
Journal:  Neuron       Date:  2020-06-10       Impact factor: 17.173

2.  Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis.

Authors:  Michael E Ward; Robert Chen; Hsin-Yi Huang; Connor Ludwig; Maria Telpoukhovskaia; Ali Taubes; Helene Boudin; Sakura S Minami; Meredith Reichert; Philipp Albrecht; Jeffrey M Gelfand; Andres Cruz-Herranz; Christian Cordano; Marcel V Alavi; Shannon Leslie; William W Seeley; Bruce L Miller; Eileen Bigio; Marek-Marsel Mesulam; Matthew S Bogyo; Ian R Mackenzie; John F Staropoli; Susan L Cotman; Eric J Huang; Li Gan; Ari J Green
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

3.  TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia.

Authors:  Marka van Blitterswijk; Bianca Mullen; Alexandra M Nicholson; Kevin F Bieniek; Michael G Heckman; Matthew C Baker; Mariely DeJesus-Hernandez; Nicole A Finch; Patricia H Brown; Melissa E Murray; Ging-Yuek R Hsiung; Heather Stewart; Anna M Karydas; Elizabeth Finger; Andrew Kertesz; Eileen H Bigio; Sandra Weintraub; Marsel Mesulam; Kimmo J Hatanpaa; Charles L White; Michael J Strong; Thomas G Beach; Zbigniew K Wszolek; Carol Lippa; Richard Caselli; Leonard Petrucelli; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Ian R Mackenzie; William W Seeley; Lea T Grinberg; Bruce L Miller; Kevin B Boylan; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

4.  Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B.

Authors:  Massimiliano Stagi; Zoe A Klein; Travis J Gould; Joerg Bewersdorf; Stephen M Strittmatter
Journal:  Mol Cell Neurosci       Date:  2014-07-24       Impact factor: 4.314

5.  TMEM106B: a strong FTLD disease modifier.

Authors:  Yuetiva Deming; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2014-02-01       Impact factor: 17.088

6.  The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion.

Authors:  Zeran Li; Fabiana H G Farias; Umber Dube; Jorge L Del-Aguila; Kathie A Mihindukulasuriya; Maria Victoria Fernandez; Laura Ibanez; John P Budde; Fengxian Wang; Allison M Lake; Yuetiva Deming; James Perez; Chengran Yang; Jorge A Bahena; Wei Qin; Joseph L Bradley; Richard Davenport; Kristy Bergmann; John C Morris; Richard J Perrin; Bruno A Benitez; Joseph D Dougherty; Oscar Harari; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2019-08-27       Impact factor: 17.088

7.  The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death.

Authors:  Hiroaki Suzuki; Masaaki Matsuoka
Journal:  J Biol Chem       Date:  2016-08-25       Impact factor: 5.157

8.  Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes.

Authors:  Johanna I Busch; Travis L Unger; Nimansha Jain; R Tyler Skrinak; Rakshita A Charan; Alice S Chen-Plotkin
Journal:  Hum Mol Genet       Date:  2016-04-28       Impact factor: 6.150

9.  TMEM106B and frontotemporal lobar degeneration: can over-expression tell us how reductions are beneficial?

Authors:  Steven W Barger
Journal:  J Neurochem       Date:  2013-07-22       Impact factor: 5.372

Review 10.  What we know about TMEM106B in neurodegeneration.

Authors:  Alexandra M Nicholson; Rosa Rademakers
Journal:  Acta Neuropathol       Date:  2016-08-20       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.